Lytix moves ruxotemitide toward registrational melanoma trial after FDA backs EFS endpoint
FDA raised no objection to a randomized Phase 3 comparing neoadjuvant ruxotemitide plus pembrolizumab with pembrolizumab alone and indicated that one well-controlled study could potentially support an NDA.